AIM-listed biotechnology firm e-Therapeutics (LON: ETX) said it has started a Phase IIb trial of its ETS6103 drug, a controlled-release formulation of pain-reliever tramadol, for use in major depressive disorders.
e-Therapeutics said if the trial is positive, it intends to seek a licensing deal for the drug.
The randomised double-blind controlled trial, being conducted in the Glasgow area of Scotland with around 160 patients, is evaluating ETS6103 as a second-line treatment for patients who have not responded adequately to first-line therapy with an SSRI (selective serotonin reuptake inhibitor). It is being conducted by a group of primary care centres with a history of involvement in depression studies.
“We believe that ETS6103 has potential in this population and are working with an experienced group of clinicians to test this proposition in a randomised controlled trial,” Stephen Self, development director at e-Therapeutics, said.
e-Therapeutics expects to report the results of the trial in the first half of 2015.